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Atypical hemolytic uremic syndrome (aHUS) is associated with defective complement regulation. Disease-associated
mutations have been described in the genes encoding the complement regulators complement factor H, membrane
cofactor protein, factor B, and factor I. In this study, we show in two independent cohorts of aHUS patients that deletion
of two closely related genes, complement factor H–related 1 (CFHR1) and complement factor H–related 3 (CFHR3),
increases the risk of aHUS. Amplification analysis and sequencing of genomic DNA of three affected individuals revealed
a chromosomal deletion of ;84 kb in the RCA gene cluster, resulting in loss of the genes coding for CFHR1 and CFHR3,
but leaving the genomic structure of factor H intact. The CFHR1 and CFHR3 genes are flanked by long homologous
repeats with long interspersed nuclear elements (retrotransposons) and we suggest that nonallelic homologous
recombination between these repeats results in the loss of the two genes. Impaired protection of erythrocytes from
complement activation is observed in the serum of aHUS patients deficient in CFHR1 and CFHR3, thus suggesting a
regulatory role for CFHR1 and CFHR3 in complement activation. The identification of CFHR1/CFHR3 deficiency in aHUS
patients may lead to the design of new diagnostic approaches, such as enhanced testing for these genes.
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Introduction
Atypical hemolytic uremic syndrome (aHUS) is character-
ized by a triad consisting of microangiopathic hemolytic
anemia, thrombocytopenia, and acute renal failure in the
absence of a preceding diarrheal illness. aHUS can be either
sporadic or familial. Defective complement regulation occurs
in both sporadic and familial aHUS. Disease-associated
mutations have been described for the genes encoding the
complement regulators complement factor H (CFH), mem-
brane cofactor protein, factor I, and factor B [1–4]. In
addition, autoantibodies to factor H have been reported in
aHUS patients [5]. Recently, we showed in a family with aHUS
that nonallelic homologous recombination [6] results in the
formation of a hybrid gene derived from exons 1–21 of CFH
and exons 5–6 of complement factor H–related 1 (CFHR1) [7].
The protein product of this hybrid gene is identical to the
aHUS-associated CFH mutant S1191L/V1197A, which arises
through gene conversion [8]. CFH and the genes encoding the
five complement factor H–related proteins (CFHR1–CFHR5)
reside in a centromeric 355-kb segment on Chromosome 1.
Sequence analysis of this region provides evidence for
multiple independent large genomic duplications, also known
as low-copy repeats, resulting in a high degree of sequence
identity between CFH and CFHR1–CFHR5 [9, 10]. The
secreted protein products of these genes are related in
structure, as they are composed of repetitive units (;60
amino acids) named short consensus repeats (SCRs) [11]. In
this study, we describe a novel form of nonallelic homologous
recombination that results in the deletion of CFHR1 and
CFHR3, but leaves CFH intact. This deletion is associated with
an increased risk of aHUS.
Results/Discussion
Two cohorts of patients with aHUS have been studied, one
from Jena, Germany and one from Newcastle, United King-
dom. For the Jena cohort of 121 aHUS patients, we used
Western blotting to determine the absence of CFHR1 and
CFHR3 in serum, as demonstrated for three patients in
Figure 1A–1C. Complete absence of both CFHR1 and CFHR3
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but presence of factor H, factor H–like protein 1, CFHR2,
and CFHR4A was detected in 19 aHUS patients (16%)
compared to two out of 100 control participants (v2 ¼ 10.4,
p ¼ 0.0012, odds ratio ¼ 8.5). All 19 patients showed normal
factor H serum levels. In three of these 19 patients, DNA
analysis confirmed that the deficiency was caused by a
homozygous genomic deletion. The CFH genes were normal,
as determined by sequence analysis. Specific primers were
designed which span the 113-kb region from the 39 exons of
CFH to CFHR4 (Figure 2A). Failure of primers R2–R6 to
amplify DNA of these patients is explained by a 84-kb
deletion of a genomic fragment that includes CFHR3 and
CFHR1 and is located downstream of CFH and upstream of
CFHR4. This deletion is flanked by two duplicated segments,
B and B9, which are 28,638 bp and 28,714 bp in length,
respectively. B includes exons 21, 22, and 23 of CFH and is
located 59 of CFHR3. B9 includes exons 3, 4, and 5 of CFHR-1
and is located ;60 kb further downstream. Both segments
have the same orientation, harbor several truncated long
interspersed nuclear elements, and their sequence identity is
.98 % [12]. The position of the deletion was mapped by
amplifying regions of sequence variation between the
duplicated segments. Forward and reverse primers specific
for B and B9, respectively, generated a 9.2-kb product from
aHUS patients’ DNA, but not from control DNA. Sequence
analysis allowed the identification of nucleotides from either
B or B9 (Figure 2B), thus demonstrating fusion of B and B9 as
a result of nonallelic homologous recombination. This was
confirmed by amplification of the fused segment BB9 using
primers that also generate amplification products from
segment B and segment B9 of control DNA. Sequence analysis
of a divergent region in B and B9 confirmed that amplifica-
tion of DNA from the patient generated one product with a
single sequence (Figure 2C, upper panel), while the control
DNA generated two products with divergent sequences
(Figure 2C, middle panel), of which one is derived from
segment B and one from segment B9 (Figure 2C, lower panel).
These data demonstrate fusion of segments B and B9 in the
patient’s DNA, and confirm that this patient is homozygous
for the deletion (Figure 3A). The same results were obtained
for the other patients (unpublished data). All three patients
had identical breakpoints, which were mapped to a 1.9-kb
region of perfect homology within or directly preceding a
L1MA2 element (Figure 3B).
Figure 1. Deficiency of CFHR1 and CFHR3 in HUS
Western blotting of serum from three HUS patients (lanes 1–3) and a control subject (lane 4).
(A) Using a monoclonal antibody that reacts with the C terminus of CFHR1, complete deficiency of CFHR1 is seen in the three HUS patients. The normal
control shows the two differently glycosylated forms of CFHR1 (CFHR1a and CFHR1b, respectively).
(B) Using CFHR3 antiserum, complete deficiency of CFHR3 is seen in three HUS patients, but CFHR3 is detected in the control subject. CFHR4A is present
in all samples.
(C) The sera of the three HUS patients contain factor H–like protein 1 and the glycosylated and nonglycosylated forms of CFHR2 (CFHR2a and CFHR2,
respectively).
doi:10.1371/journal.pgen.0030041.g001
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Author Summary
Hemolytic uremic syndrome (HUS) is a severe kidney disease, which
is characterized by hemolytic anemia, thrombocytopenia, and acute
renal failure. The nondiarrhea-associated form, also known as
atypical HUS (aHUS), is rare, sometimes familial, often recurrent,
and has a poor outcome. Several studies have shown that aHUS is
associated with mutations in genes coding for complement
regulators, which leads to defective regulation of complement
activation, particularly at cell surfaces. We report a novel suscept-
ibility factor for aHUS in the form of a chromosomal deletion of a
large (;84 kb) genomic fragment in the regulators of complement
activation gene cluster at Chromosome 1q32. This deletion is a
result of nonallelic homologous recombination and leads to the loss
of two genes, CFHR1 and CFHR3, which encode factor H–related
proteins 1 and 3, respectively. We recommend diagnostic screening
of aHUS patients for these susceptibility factors.
The Newcastle cohort of 66 aHUS patients was investigated
using multiplex ligation–dependent probe amplification
(MLPA) [13] to measure copy number of CFHR1 exons 2
and 3 (Table 1). The data show that deletion of CFHR1 is
strongly associated with aHUS. In the aHUS group, 28% of
the patients had this deletion, compared to 6% of the control
group (v2 ¼ 33.2, p ¼ 1.0 3 108, odds ratio ¼ 6.3). The
following copy numbers of CFHR1 were found in aHUS
patients: zero copies, 10%; one copy, 35%; two copies, 55%.
In control subjects, the copy numbers were: zero copies, 2%;
one copy, 9%; and two copies 89% (v2¼ 28.7, p¼ 5.93 107).
The allele frequency of CFHR1 deletion was 30% in those
patients known to carry a mutation and 27% in those without
a mutation (v2 ¼ 0.16, p ¼ 0.69).
The functional effect of complete deficiency of CFHR1 and
CFHR3 proteins was investigated using a modified version of
a hemolytic assay with factor H–depleted plasma and sheep
erythrocytes [14, 15]. Addition of heat-inactivated serum
from the three patients caused increased erythrocyte lysis
(Figure 4). In contrast, serum derived from a healthy
individual showed dose-dependent protection. These data
show that CFHR1/CFHR3–deficient plasma has reduced
protective activity and suggest that the absence of CFHR1
and/or CFHR3 contributes to the defective regulation of
complement activation on cell and tissue surfaces. This is
underlined by the fact that these patients have normal serum
levels of factor H and factor I. Similarly, we previously
showed that mutant factor H derived from HUS patients
displayed reduced cell binding and protection activities [16].
In this study we report that hetero- and homozygous
deletion of CFHR1 and CFHR3 through nonallelic homolo-
gous recombination events downstream of CFH is associated
Figure 2. Map of the Human Factor H Gene Cluster
(A) The 20 SCRs of CFH, the five SCRs of CFHR3, the fiveSCRs of CFHR1, and the nine SCRs of CFHR4 are indicated by vertical bars. The position of the two
duplicated homologous segments (B and B9) and that of the eight primer pairs (R1–R8) is shown. Failure () to amplify DNA downstream of CFH in the
three HUS patients reveals a deletion of a genomic ;84-kb fragment.
(B) Sequence comparison of segment B (red) and segment B9 (yellow) reveals blocks with sequence diversity. Fusion of the homologous segments and
localization of the breakpoints in three CFHR1/CFHR3 deficient HUS patients are indicated. Fusion of segments B and B9 is demonstrated by
amplification of a 9.2-kb PCR fragment using a forward primer specific for segment B and a reverse primer specific for segment B9. For all three patients,
sequences of block 1 are derived from segment B (red) and sequences of block 2 are derived from segment B9 (yellow).
(C) Similar PCR products were generated with primers common for segment B and segment B9. Amplification of both segments is confirmed by
sequence analysis. Sequence of PCR products from the patient is identical to segment B of a control DNA (upper panel). Sequence of PCR products of a
control person is identical to segment B and B9 (middle panel). Identification of sequence B9 of the control person (lower panel). Sequence differences
between segment B and segment B9 are indicated (grey bar).
doi:10.1371/journal.pgen.0030041.g002
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with an increased risk of aHUS. aHUS patients with
deficiency of CFHR1/CFHR3 are characterized by a relatively
young age (1–21 y) at disease onset. Previously, we showed
that deletion of CFHR1 and CFHR3 reduces the risk of age-
related macular degeneration [17]. It is fascinating that the
same polymorphic variant is associated with opposite effects:
an increased risk for HUS and a decreased risk for age-related
macular degeneration. How could this deletion be acting?
One possibility is that the absence or presence of either
CFHR1 and/or CFHR3 has a disease-modifying action.
Although each of the two proteins alone lacks cofactor and
decay-accelerating activity, CFHR3 has a cofactor-enhancing
activity [18]. In addition, both CFHR1 and CFHR3 bind C3b
and heparin, thus suggesting a regulatory function in C3b
processing [18].
Another possibility is that the deletion is in linkage
disequilibrium with other susceptibility alleles in CFH or
that it may affect CFH transcription. Understanding the
functional effect of this disease-modifying deletion will help
to extend our understanding of the role of complement in
the pathogenesis of both aHUS and age-related macular
degeneration.
Materials and Methods
Participants. Newcastle. Sixty-six patients from Newcastle with a
clinical diagnosis of aHUS were included in this study. Within this
group, 15 were known to carry a CFH mutation, two carried a
membrane cofactor protein mutation, and three carried a factor I
mutation. Screening with MLPA for exons 22 and 23 of CFH showed
that none of these patients carried a hybrid CFH/CFHR1 gene. The
allele frequency of CFHR1 deletion in the aHUS patients was
compared to 119 samples of human control DNA from a randomly
selected population (healthy blood donors) obtained from the
European Collection of Cell Cultures (http://www.ecacc.org.uk). The
study was approved by the Northern and Yorkshire Multi-Centre
Research Ethics Committee.
Figure 3. Chromosomal Rearrangement of Segments B and B9
(A) Homologous recombination between segments B and B9 in the RCA gene cluster results in deletion of the genes coding for CFHR1 and CFHR3 and
fusion of segments B and B9 as described in the text.
(B) The B and B9 segments in the factor H gene cluster are characterized by high sequence identity (98%) and include several truncated long
interspersed nuclear elements (retrotransposons). The breakpoint identified in all three patients is indicated by the arrow.
doi:10.1371/journal.pgen.0030041.g003
Table 1. Frequency of CFHR1 Deletion and Copy Number of CFHR1 Exons 2 and 3 in aHUS Patients and Controls (Newcastle Cohort)
Study Participants CFHR1 Allele Frequencya CFHR1 Copy Numberb
Deleted Present 0 1 2
aHUS patients 37 95 7 23 36
Controls 15 223 2 11 106
av2¼ 33.2, p¼ 1.03 108
bv2¼ 28.7, p¼ 5.93 107
doi:10.1371/journal.pgen.0030041.t001
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Jena. A total of 121 aHUS patients from Jena were included in this
study. Of these, 19 were found to be deficient in CFHR1 and CFHR3.
Genomic deletion of CFHR1 and CFHR3 genes was determined in
three patients (Table 2). None of these three patients carried a hybrid
CFH/CFHR1 gene. The study was approved by the Research Ethics
Committee of the University of Cologne, Germany, and by the
Research Ethics Board of the Hospital for Sick Children, Toronto,
Canada.
Sera and Western blot analysis. Serum samples from 121 aHUS
patients (Jena cohort) and 100 anonymous healthy blood donors were
assayed for the presence and mobility of factor H and CFHR1. Serum
was separated by SDS-PAGE, transferred onto a membrane, and
incubated with polyclonal factor H antiserum (Calbiochem-Novabio-
chem, http://www.emdbiosciences.com) or monoclonal C18 antibody
[19], which identifies an epitope in factor H and CFHR1. CFHR3 was
detected with polyclonal CFHR3 antiserum [20].
Genetic analysis. Genomic DNA was prepared from peripheral
blood cells of three patients. Genomic DNA was amplified by PCR
using specific primers R1–R8 that cover the 100-kb region down-
stream of the factor H gene (Table 3). Amplification of the
breakpoint region and sequence analysis was performed using
primers P9.2 and B1 and B2. For amplification of segment B and
B9, primer P was used. The sequence of the amplified products was
determined using an ABI 3100 sequence analyzer (Applied Biosys-
tems, www.appliedbiosystems.com). The sequences were compared to
that of the genomic DNA of Chromosome 1. The sequences of
segment B and segment B9 were compared and analyzed for repeat
content using CENSOR (http://www.girinst.org).
Erythrocyte lysis assay. Factor H–depleted human plasma was
prepared by immunoadsorbance of factor H from normal human
plasma. Polyclonal factor H antiserum (Merck Biosciences, http://
www.merckbiosciences.co.uk) was covalently coupled to a 1-ml
HiTrap NHS (N-hydroxy succimide) column (GE Health Care,
http://www.gehealthcare.com). Factor H depletion was confirmed by
Western blotting, and ELISA showed that about 66% of the protein
was removed. Depleted plasma was directly used for hemolytic assays.
Hemolytic experiments were performed in VBS buffer (veronal
buffered saline, 144 mM NaCl, 7 mM MgCl2, and 10 mM EGTA, pH
7.4). Increasing amounts of heat-inactivated (10 min at 56 8C) CFHR1/
CFHR3–deficient serum or control serum were added to the depleted
plasma and 23 107 sheep erythrocytes. Following incubation at 37 8C
for 30 min, the mixture was cleared by centrifugation and the
absorbance in the supernatants was measured at 414 nm. Using
human complement active plasma sheep erythrocytes serve as non-
activators of complement. These cells are protected from lysis and no
hemoglobin is released. However, when factor H is depleted from
human plasma, this plasma has the ability to lyse sheep erythrocytes,
as demonstrated by the release of hemoglobin and an increase in
absorbance. Addition of purified factor H or normal human heat-
inactivated serum reconstitutes protection of erythrocytes [15].
Multiplex ligation–dependent probe amplification. The MLPA
reaction has been previously described [13]. In this study, a
completely synthetic probe set was used, obviating the need for a
cloning step in the production of probes. Probes were designed to
determine dosage for exons 2 and 3 of CFHR1, along with control
probes for MSH2 exon 1 and MLH1 exon 19. Each probe pair
hybridises to immediately adjacent targets at the sequence of interest.
Hybridisation sequences are shown in Table 4. Probe pairs also
contain binding sites for primers used in the MLPA reaction, as well
as stuffer sequence to ensure that each amplified probe product is of
a unique length. Oligonucleotides were obtained from TAG New-
castle, (http://www.vhbio.com). Righthand probes were 59-phosphory-
lated and purified by desalting.
Reagents for the MLPA reaction were purchased from MRC-
Holland (http://www.mrc-holland.com). The ligation reactions were
carried out according to the manufacturer’s recommended protocol
using 100–200 ng of genomic DNA and 2 fmol of probe. Incubations
and PCR amplification were carried out on a DNA Engine Tetrad 2
thermal cycler (http://www.bio-rad.com). Amplified products were
diluted 10-fold to give peak heights within the quantitative range
(approximately 100–4,000 units) on the ABI PRISM 3130 Genetic
Analyzer capillary electrophoresis system (Applied Biosystems,
http://www.appliedbiosystems.com). Diluted product (1 ll) and
0.5 ll of ROX 500 internal size standard (Applied Biosystems) were
made up to 10 ll using dH2O and samples were run on the ABI
3130. Peak areas for each sample were determined using the
proprietary Genemapper software (Applied Biosystems) and dosage
quotients calculated.
Figure 4. Defective Protective Activity with CFHR1/CFHR3 Deficient
Plasma
A novel type of hemolytic assay was used to analyze hemolytic activity of
CFHR1/CFHR3 deficient human serum. Sheep erythrocytes were incu-
bated with factor H–depleted human plasma. Sheep erythrocytes
generally act as nonactivators of complement in human plasma.
However, depletion of factor H from the plasma converts the sheep
erythrocytes into activator surfaces (ctrl, empty circle). Addition of heat
inactivated serum to depleted plasma as a source of factor H has a dose-
dependent protective effect (‘‘control’’). Compared to normal human
serum, sera of patient P1 to P3 with CFHR1/CFHR3 deficiency showed
less protective activity as indicated by the increased lysis of erythrocytes.
The classical pathway of complement activation was inhibited by the
chelating agent EGTA. Erythrocytes incubated in buffer do not lyse (ctrl,
filled circle). Mean values and standard deviations of three separate
experiments are shown.
Ctrl, control
doi:10.1371/journal.pgen.0030041.g004
Table 2. Profile of Three Patients Deficient in CFHR1 and CFHR3
Patient Diagnosis Age
[y]
Age at Disease
Onset [y]
Factor H
[mg/L](230–750)
Therapy Outcome
P1 D HUS 14 13 3/12 542 i.v. FFP q 14 days; antihypertensives No signs of disease activity; renal function
slightly decreased; mild hypertension
P2 D HUS 18 13 10/12 596 Plasmapheresis; i.v. FFP infusion;
steroids; antihypertensives
Normal renal function; no chronic
treatment required
P3 D HUS 11 11 1/12 375 i.v. FFP q 14 days; steroids;
antihypertensives
No signs of disease activity; renal function
improving; mild hypertension
Renal biopsy in all patients showed thrombotic microangiopathy with acute and chronic changes.
D: no diarrhea at disease onset; FFP: fresh frozen plasma.
doi:10.1371/journal.pgen.0030041.t002
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CFHR1_ex3R ACAGTATCACCTTCCAGATGTGTTTG
ATCTCTAGATTGGATCTTGCTGGCAC
MLPA primer binding sites are shown in bold, exon-specific sequences in red, and stuffer
sequence in italics.
doi:10.1371/journal.pgen.0030041.t004
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